Delving into the Latest Updates on Finasteride with Synapse

Overview

Basic Info

SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH.

Drug Type

Small molecule drug

Synonyms

(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride, Finasteride (JAN/USP/INN)

+ [55]

Target

5α-reductase

Action

inhibitors

Mechanism

5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesUrogenital DiseasesNeoplasms

Active Indication

Androgenetic AlopeciaProstatic HyperplasiaAlopecia+ [1]

Inactive Indication

Alopecia, Male PatternHematuriaHemospermia

Originator Organization

Active Organization

+ [8]

Inactive Organization

Merck Sharp & Dohme Corp.Polichem SA (Switzerland)Merck Frosst Canada Ltd.

+ [2]

License Organization

Inventage Lab, Inc.

Shanghai Pharmaceutical Co., Ltd.

Polichem SA

+ [9]

Drug Highest PhaseApproved

First Approval Date

United States (19 Jun 1992),

Prostatic Hyperplasia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H36N2O2

InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N

CAS Registry98319-26-7

Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.

Start Date01 Oct 2027

Sponsor / Collaborator

VA Office of Research and Development

[+5]

NCT07731802

/ Not yet recruitingPhase 4IIT

Finasteride and Cutibacterium

High levels of Testosterone causes high amounts of skin bacteria (Cutibacterium Acnes) which can go into the skin during a shoulder replacement surgery and cause a terrible infection.
The goal of this experiment is to have participants take Finasteride, a medication that blocks testosterone production, for 2 weeks and evaluate the following:
* Blood levels of testosterone
* Amount of bacteria on the skin.
Participants will:
* Be assigned to take Finasteride, or a placebo (a look-alike pill with no active medicine) once daily, for 2 weeks
* Have a small sample of their blood collected and their skin swabbed with a Q-tip to determine Testosterone levels and bacteria on the skin
* Blood draw and skin testing will take place before starting Finasteride or the placebo (day 0) and at the end of the experiment (day 14).

Start Date31 Aug 2026

Sponsor / Collaborator

University of Washington

TCTR20260327010

/ Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two treatment and two-sequence of Finasteride Tablets 1 mg relative to Propecia in healthy Thai male participants under fasting condition.

Start Date17 Jun 2026

Sponsor / Collaborator

Bio-innova Co., Ltd

100 Clinical Results associated with Finasteride

Login to view more data

100 Translational Medicine associated with Finasteride

Login to view more data

100 Patents (Medical) associated with Finasteride

Login to view more data

3,585

Literatures (Medical) associated with Finasteride

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System

Article

Author: Williams, Greg ; Bamimore, Mary A. ; Gupta, Aditya K. ; Talukder, Mesbah

BACKGROUND:

Oral finasteride 1 milligram (1 mg) daily-which is a 5-alpha reductase inhibitor (5-ARI) approved by the Food and Drug Administration (FDA) for androgenetic alopecia-is linked to sexual adverse events (AEs). However, it remains unclear whether this link is causal or merely correlational.

METHODS:

In FAERS, AEs are described by preferred terms (pts) of the Medical Dictionary for Regulatory Activities system; we investigated 8 AEs, including erectile dysfunction (pt = 10,061,461). We determined if signals could be detected with finasteride 1 mg-and 0.5 mg of dutasteride (a more potent 5-ARI)-in FAERS, for sexual AEs related to the post-finasteride syndrome (PFS): for the two, we identified the yearly number of cases (i.e. reports with sexual AEs) from 2006 to 2024. For each AE, we conducted a disproportionality analysis where reporting odds ratios (RORs) were estimated-along with p-values and 95% confidence intervals (CIs).

RESULTS:

There were more reports with finasteride 1 mg than with dutasteride 0.5 mg; for both, more reporting was observed as of 2012, the year the PFS foundation formally propagated PFS awareness.

CONCLUSIONS:

Our findings support that the disproportionately higher reporting of sexual AEs with finasteride 1 mg than with dutasteride 0.5 mg-even more so after 2012-could be attributed to the nocebo effect.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

Article

Author: Chen, Liming ; Hu, Binyi ; Gu, Qun ; Zhang, Jiaojiao ; Xiao, Meng ; Li, Yanting ; Ding, Ziyan ; Zhang, Jianzhong ; Huang, Fan ; Zhang, Hui ; Liu, Yian ; Zhou, Cheng ; Ding, Rui ; Men, Fang ; Zhao, Wenyan ; Wang, Qian ; Yu, Baohui ; Fang, Yi ; Niu, Suping ; Li, Shuang

OBJECTIVES:

Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males with androgenetic alopecia (AGA).

METHODS:

In this randomized, double-blind, placebo-controlled trial, 44 subjects received single and multiple doses across five cohorts with varying finasteride concentrations (0.025%-0.1%) and frequencies. Safety, tolerability, and pharmacokinetics were evaluated. The concentrations of minoxidil-finasteride were both measured.

RESULTS:

The result shows that CG2001 was safe and well-tolerated, with no serious adverse events. Systemic minoxidil exposure was consistent across most dosages, while finasteride exposure increased dose- and frequency-dependently, though it remained markedly lower than that reported with oral administration. Steady state was achieved for both drugs after 7 days.

CONCULSIONS:

The favorable safety profile and reduced systemic finasteride exposure position CG2001 as a promising alternative, supporting further clinical development in a phase IIa trial, and provide a pharmacokinetic foundation for subsequent efficacy trials in patients with AGA.

01 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.

Review

Author: Lucas-Abellán, Carmen ; Rabadán-Ros, Rubén ; González-Louzao, Rebeca ; Victoria-Montesinos, Desirée ; El Ammari, Chaimae ; Zapata-Pérez, Rubén ; García-Muñoz, Ana María

BACKGROUND:

Non-scarring alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium, is highly prevalent and often associated with significant psychosocial burden. Although treatments such as minoxidil and finasteride are available, variability in response and tolerability concerns have increased interest in alternative therapeutic approaches. Polyphenolic compounds have attracted attention due to their antioxidant, anti-inflammatory, and immunomodulatory properties.

OBJECTIVES:

This systematic review and meta-analysis evaluated the efficacy of oral and topical polyphenolic interventions for hair regeneration in adults with non-scarring alopecia.

METHODS:

A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted according to PRISMA 2020 guidelines (PROSPERO: CRD420251230149). Randomized, blinded controlled trials were included. Primary outcomes were objective trichoscopic measures, including hair density and total area hair count.

RESULTS:

Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes.

CONCLUSIONS:

Current evidence suggests that selected polyphenolic formulations may represent a potential adjunctive therapeutic approach in non-scarring alopecia, though further standardized and long-term trials are warranted.

132

News (Medical) associated with Finasteride

12 Aug 2026

·www.prnewswire.com

Amplifica Completes $26 Million Series B Financing to Advance Injectable Pipeline for Hair Growth

Oversubscribed round with proceeds to support continued clinical development SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Amplifica Holdings Group, Inc. ("Amplifica"), a privately held, clinical-stage biopharmaceutical company developing novel therapies for hair growth, today announced the closing of an oversubscribed $26 million Series B Preferred Stock financing. The financing was led by Tasso Partners, LLC, with participation from Eli Lilly and Company, principals of Scopia Capital Management, LP, and other new and existing investors. Proceeds will be used to advance clinical development of the Company's novel pipeline candidates, which are designed to reactivate dormant hair follicles and promote the growth of new hair. Currently marketed products are primarily intended to slow or prevent further hair loss. "Closing this oversubscribed round reflects strong investor conviction in the science behind our injectable approach and in the size of the opportunity it addresses," remarked Frank Fazio, President and CEO. "This capital allows us to accelerate our mission to deliver next-generation products to patients confronting the physical and emotional challenges of hair loss." Androgenetic alopecia is estimated to affect more than 50 million men and 30 million women in the United States. Existing daily-use treatments such as finasteride and minoxidil, though considered the standard of care, have delivered only modest improvements in hair count, and their daily-use profile introduces challenges including poor patient compliance, tolerability and side-effect concerns, and limited efficacy and applicability in women. These ongoing limitations have hindered broader adoption and further underscore the need for innovation in this space. "Amplifica has built a proprietary portfolio of signaling molecules that regulate the hair follicle growth cycle, and this financing advances them further into clinical development," said Wajdie Ahmad, Co-Founder and Executive Chairman. "Our discovery platform has yielded candidates that activate follicle regeneration through distinct, complementary mechanisms of action. Advancing multiple mechanisms in parallel maximizes our probability of clinical success and reinforces our leadership in hair regeneration for men and women." With this financing, the Company embarks on its next growth phase, focusing its attention on clinical development activities within its injectable product pipeline. About Amplifica Holdings Group, Inc. Amplifica is a clinical-stage biopharmaceutical company focused on developing novel treatments to address androgenetic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The Company is taking a nature-inspired scientific approach using a molecular mechanism that regrows natural hair. The Company has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair. Amplifica will be initiating product development programs and clinical trials to evaluate the safety and efficacy of its core technology, as well as obtain all applicable regulatory approvals. For more information, please visit . Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions. These forward-looking statements are based on the Company's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding the potential efficacy of the Company's product candidates, the Company's expectations with respect to development and commercialization of the Company's product candidates, the initiation or completion of any future clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release, and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contact(s) Company [email protected] Media EvolveMKD – [email protected] SOURCE Amplifica Holdings Group, Inc. 21% more press release views with Request a Demo

12 Aug 2026

·allsci.com

UC Irvine alopecia spinout Amplifica gets Lilly backing in USD 26m Series B

San Diego-based Amplifica Holdings Group, Inc., a biopharma with a pipeline of injectable therapies for androgenetic alopecia (AGA), has closed an oversubscribed USD 26 million Series B financing. Funding will support its pipeline of biological signaling molecules designed to reactivate dormant hair follicles rather than simply slow hair loss. Tasso Partners, LLC led the round, with participation from Eli Lilly and Company, principals of Scopia Capital Management, LP, and other new and existing investors. The financing brings total disclosed funding to approximately USD 37.8 million, following a USD 11.8 million Series A in October 2022 facilitated by SternAegis Ventures. Amplifica is a spinout from the University of California, Irvine, where Co-Founder and Chief Scientific Officer Maksim Plikus, a professor in the Department of Developmental and Cell Biology, conducted the foundational research underpinning both lead candidates. The company holds an exclusive worldwide license from the Regents of the University of California covering the core intellectual property. Its most advanced asset, AMP-303, is an intradermal injectable that mimics osteopontin signaling to drive conversion of miniaturized vellus hairs into terminal hairs. The molecule's mechanism derives from observations that senescent melanocytes in congenital nevi secrete osteopontin, which activates hair follicle stem cells via the CD44 receptor — producing the visibly denser hair characteristic of hairy moles. AMP-303 completed a randomized, double-blind, placebo-controlled Phase I trial, with results reported in September 2024 and subsequently presented at the Society for Investigative Dermatology Annual Meeting in May 2025. The second pipeline candidate, AMP-506, is based on SCUBE3, a secreted signaling protein produced by dermal papilla cells that initiates the anagen growth phase via a Hedgehog–SCUBE3–TGF-β cascade. Amplifica licensed the SCUBE3 technology exclusively from UC Irvine in January 2023, and AMP-506 is currently in IND-enabling studies. In the same month, the company entered a research and development collaboration with UK-based industrial biotechnology firm Ingenza to support bioprocess development for its biological candidates. Existing daily-use treatments for AGA, including finasteride and minoxidil, are primarily intended to slow further loss rather than regenerate hair. Amplifica's injectable approach, targeting distinct endogenous signaling pathways, is designed to address that limitation, though clinical validation beyond Phase I for AMP-303 remains ongoing. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

Phase 1License out/in

16 Jul 2026

·www.biopharmadive.com

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

Dive Brief:Veradermics on Wednesday delivered another research win for its experimental baldness drug, showing it can help women with mild-to-moderate pattern hair loss.The pill, known as VDPHL01, is an extended-release version of minoxidil, sold for decades under the brand name Rogaine. Veradermics theorized that prolonging exposure to the medicine would allow more consistent and intense hair growth while avoiding spikes of drug concentration that can cause side effects.The new Phase 2 study followed 28 women who took the pill either once or twice a day. Results across both groups were similar, with a mean increase of about 23 hairs per square centimeter after six months of treatment. Importantly, a majority of participants and researchers reported seeing improvement at the earliest check-in point of two months, Veradermics said.Dive Insight:The results exceeded investor expectations and built on a successful study in male pattern baldness released in April. The data keep the momentum going and should give investors more confidence in the ongoing Phase 3 program, Leerink Partners analyst Marc Goodman wrote in a note to clients.Investors had been looking for an increase of between 15 and 20 hairs per square centimeter, Cantor analyst Prakhar Agrawal wrote in a note to clients. The strong results, coupled with a lack of serious side effects, prompted him to increase his sales estimate to $2.1 billion in 2033, with females accounting for about 40% of the revenue. Previously, he forecast 2033 sales of $1.8 billion, with about $550 million coming from women.Veradermics is part of a wave of young companies pursuing solutions for hair loss, long a neglected area of study by the pharmaceutical industry. The two big brands in hair loss, Rogaine and Propecia, were both discovered by accident, with Rogaine originally developed as a blood pressure medication and Propecia as a treatment for enlarged prostate glands.The Food and Drug Administration approved Rogaine in 1988 and Propecia in 1997 to treat baldness. They are now available in cheap, generic versions but both have drawbacks that Veradermics and other startups are trying to address. The companies also say they see a huge underserved population of people who care very much about hair loss.For women, especially, losing hair can feel like losing your identity, Veradermics CEO Reid Waldman said during a conference call with analysts and investors Wednesday. This transcends being aesthetic. Its deeply personal, its deeply psychological and its essentially universal, affecting 30 million women in the U.S. at any given time.While Veradermics is repurposing and improving on a well-known drug, other companies are trying entirely new approaches. Pelage Pharmaceuticals, backed by the prominent investment firms GV and Arch Venture Partners, is developing a topical gel to activate dormant hair follicle stem cells.Absci, which counts Eli Lilly among its investors, used an artificial intelligence-driven discovery platform to unearth an antibody that might spur hair growth.Veradermics went public in February, offering about 15 million shares at $17 a piece. Since then, the companys stock has skyrocketed, reaching nearly $130 Wednesday before falling back to about $116 early Thursday. The company plans to release topline results from a second Phase 3 trial in men in the second half of this year and expects to read out initial data from a Phase 2/3 study in women in the first half of 2027. '

Clinical ResultPhase 3Phase 2

100 Deals associated with Finasteride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00321	Finasteride	G04CB01 D11AX10	DB01216

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Androgenetic Alopecia	United States	Organon & Co.	19 Dec 1997
Prostatic Hyperplasia	United States	Organon & Co.	19 Jun 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia, Male Pattern	Phase 3	Belgium	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Germany	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Hungary	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Russia	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Spain	Polichem SA (Switzerland)	02 Aug 2016
Hematuria	Phase 2	Canada	Merck Frosst Canada Ltd.	01 Mar 2008
Hemospermia	Phase 2	Canada	Merck Frosst Canada Ltd.	01 Mar 2008
Alopecia	Preclinical	United States	Avidence Therapeutics Inc.	01 Mar 2026
Triple Negative Breast Cancer	Preclinical	China	Kunming University of Science & Technology	01 Sep 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2026	Not Applicable	Renal Cell Carcinoma	185	5-ARIs (finasteride/dutasteride) exposed	bfzltbekps(anumfciumm) = qctwhjbxsh sbfnndrgii (aluyomvcyy ) View more	Positive	26 Feb 2026
				Non-5-ARIs exposed	bfzltbekps(anumfciumm) = dvazemvamq sbfnndrgii (aluyomvcyy ) View more
NCT02248701 (Pubmed \| Front Neurol)	Phase 2	Spinal Cord Injuries testosterone \| estradiol \| dihydrotestosterone	12	High-dose Testosterone + Finasteride	auqkwdjzrf(zsmillwxff) = reduced more than vehicle+placebo at 12 months yjwiglpnmp (jkdcpuaojl ) View more	Positive	11 Dec 2024
NCT02213107 (phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI), CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Prostatic Cancer \| Localized Prostate Carcinoma ... View more	43	finasteride+Enzalutamide+Dutasteride	xkrhivvead = nhzpddzjuq bzzpwonhnf (melgfcccsh, gksgnpnizd - nikkhxnxrh) View more	-	13 Nov 2024
NCT02213107 (ASCO2024) Manual	Phase 2	Castration-sensitive prostate cancer	43	Enzalutamide 16Dutasteride+ DFinasteride0.5mg daily	byqceyeadu(vbmkzklorg) = ihkeyuotav nffrcsfnkf (nshxjibfcg ) View more	Positive	24 May 2024
NCT02248701 (CTgov)	Phase 2	Hypogonadism \| Genital Diseases, Male \| Spinal Cord Injuries	33	Finasteride+Testosterone Enanthate (Testosterone Enanthate, Finasteride)	aydnmrvlln(dupwxvisnu) = fvzvuegewr drwilvtyau (fgmxdbjiih, 4.7) View more	-	29 Sep 2023
				Placebo pill (Placebo Treatment)	aydnmrvlln(dupwxvisnu) = wdmgtoowlz drwilvtyau (fgmxdbjiih, 2.4) View more
MP38-07 (AUA2022)	Not Applicable	Sexual Dysfunction DHT \| testosterone \| calculated free T	91	Men with persistent sexual dysfunction after discontinuation of Finasteride	ztqiebqctu(mhrcwqhrcu) = enqbosanqg auqldswkee (qlxmiqjghf ) View more	-	01 May 2022
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	Not Applicable	Non-metastatic prostate cancer	74	bicalutamide+leuprolide+goserelin (SOC Cohort)	cbarfvefmk(msbxckxsno) = udfxiaiezi ltrqooiedk (shcolusyds, 0.04) View more	-	28 Oct 2021
				finasteride+dutasteride+bicalutamide (Oral ADT Group)	cbarfvefmk(msbxckxsno) = hcgmpmixlo ltrqooiedk (shcolusyds, 0.04) View more
NCT02213107 (ESMO2020)	Phase 2	Prostatic Cancer	43	Enzalutamide 160mg daily + Dutasteride 0.5mg daily	jvxwjfoyem(zwmvjyjuay) = the most common any grade AE was fatigue (65%) aohyzwafew (mlgvnynara ) View more	Positive	17 Sep 2020
				Enzalutamide 160mg daily + Finasteride 5mg daily
NCT02213107 (ASCO2019)	Phase 2	Prostatic Cancer	43	Enzalutamide 160 mg/day + Dutasteride 0.5 mg/day	yohwjaxvjc(pibdvgwkeh) = cwiptfncmb qvxtpwxnud (ivgyujdiid ) View more	Positive	26 May 2019
NCT03004469 (CTgov)	Phase 3	Androgenetic Alopecia \| Alopecia, Male Pattern	458	P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo)	njchefdpwc(bcrykfwocc) = mrxnytbane wshetxycmv (evuavbabzu, 2.88) View more	-	19 Apr 2019
				Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo)	njchefdpwc(bcrykfwocc) = edfhuguxdf wshetxycmv (evuavbabzu, 3.01) View more